» Articles » PMID: 34859063

Importance of Tricuspid Regurgitation Velocity Threshold in Risk Assessment of Pulmonary Hypertension-Long-Term Outcome of Patients Submitted to Aortic Valve Replacement

Overview
Date 2021 Dec 3
PMID 34859063
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The upper physiological threshold for tricuspid regurgitation velocity (TRV) of 2.8 m/s proposed by the Pulmonary Hypertension (PH) guidelines had been questioned. The aim of this study was to evaluate the prognostic significance of preoperative PH in patients with aortic stenosis, long-term after valve replacement, using two different TRV thresholds (2.55 and 2.8 m/s). Four hundred and forty four patients were included (mean age 73 ± 9 years; 55% male), with a median follow-up of 5.8 years (98% completed). Patients were divided into three PH probability groups according to guidelines (low, intermediate and high) for both thresholds (TRV ≤ 2.8 m/s and TRV ≤ 2.55 m/s), using right atrial area>18 cm and right ventricle/left ventricle ratio>1 as additional echocardiographic variables. In patients with measurable TRV ( = 304), the low group mortality rate was 25% and 30%, respectively for 2.55 and 2.8 m/s TRV thresholds. The intermediate group with TRV > 2.55 m/s was an independent mortality risk factor (HR 2.04; 95% CI: 1.91 to 3.48, = 0.01), in contrast to the intermediate group with TRV>2.8 m/s (HR 1.44; 95% CI: 0.89 to 2.32, = 0.14). Both high probability groups were associated with an increased mortality risk, as compared to their respective low groups. When including all patients (with measurable and non-measurable TRV), both intermediate groups remained independently associated with an increased mortality risk: HR 1.62 (95% CI 1.11 to 2.35 = 0.01) for the new cut-off point; and HR 1.43 (95% CI: 0.96 to 2.13, = 0.07) for guidelines threshold. A TRV threshold of 2.55 m/s, together with right cavities measures, allowed a better risk assessment of patients with PH secondary to severe aortic stenosis, with or without tricuspid regurgitation.

Citing Articles

Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER-MRI studies.

Lawrie A, Chin K, Fong Y, Gargano C, Gitton X, He C Pulm Circ. 2024; 14(2):e12386.

PMID: 38868397 PMC: 11167234. DOI: 10.1002/pul2.12386.


S100 proteins in cardiovascular diseases.

Zhou Y, Zha Y, Yang Y, Ma T, Li H, Liang J Mol Med. 2023; 29(1):68.

PMID: 37217870 PMC: 10204201. DOI: 10.1186/s10020-023-00662-1.

References
1.
Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G . A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011; 365(1):44-53. DOI: 10.1056/NEJMoa1005565. View

2.
Badano L, Hahn R, Rodriguez-Zanella H, Garaygordobil D, Ochoa-Jimenez R, Muraru D . Morphological Assessment of the Tricuspid Apparatus and Grading Regurgitation Severity in Patients With Functional Tricuspid Regurgitation: Thinking Outside the Box. JACC Cardiovasc Imaging. 2019; 12(4):652-664. DOI: 10.1016/j.jcmg.2018.09.029. View

3.
Nemoto N, Lesser J, Pedersen W, Sorajja P, Spinner E, Garberich R . Pathogenic structural heart changes in early tricuspid regurgitation. J Thorac Cardiovasc Surg. 2015; 150(2):323-30. DOI: 10.1016/j.jtcvs.2015.05.009. View

4.
Cladellas M, Garcia-Ribas C, Ble M, Gomez M, Farre N, Mas-Stachurska A . Impact of Preoperative Measurement of Right Heart Chambers in the Evaluation of Pulmonary Hypertension Following Aortic Valve Replacement. Chest. 2020; 157(6):1597-1605. DOI: 10.1016/j.chest.2019.12.017. View

5.
Dreyfus G, Corbi P, Chan K, Bahrami T . Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair?. Ann Thorac Surg. 2004; 79(1):127-32. DOI: 10.1016/j.athoracsur.2004.06.057. View